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Abstract
Mammalian target of rapamycin (mTOR) is the core component of two complexes, mTORC1 and 
mTORC2. mTORC1 is inhibited by rapamycin and analogues. mTORC2 is impeded only in some 
cell types by prolonged exposure to these compounds. mTOR activation is linked to tubular cell 
proliferation in animal models and human autosomal dominant polycystic kidney disease 
(ADPKD). mTOR inhibitors impede cell proliferation and cyst growth in polycystic kidney 
disease (PKD) models. After renal transplantation, two small retrospective studies suggested that 
mTOR was more effective than calcineurin inhibitor-based immunosuppression in limiting kidney 
and/or liver enlargement. By inhibiting vascular remodeling, angiogenesis, and fibrogenesis, 
mTOR inhibitors may attenuate nephroangiosclerosis, cyst growth, and interstitial fibrosis. Thus, 
they may benefit ADPKD at multiple levels. However, mTOR inhibition is not without risks and 
side effects, mostly dose-dependent. Under certain conditions, mTOR inhibition interferes with 
adaptive increases in renal proliferation necessary for recovery from injury. They restrict Akt 
activation, nitric oxide synthesis, and endothelial cell survival (downstream from mTORC2) and 
potentially increase the risk for glomerular and peritubular capillary loss, vasospasm, and 
hypertension. They impair podocyte integrity pathways and may predispose to glomerular injury. 
Administration of mTOR inhibitors is discontinued because of side effects in up to 40% of 
transplant recipients. Currently, treatment with mTOR inhibitors should not be recommended to 
treat ADPKD. Results of ongoing studies must be awaited and patients informed accordingly. If 
effective, lower dosages than those used to prevent rejection would minimize side effects. 
Combination therapy with other effective drugs could improve tolerability and results.
Careful clinical observations have been key to the identification of the genes mutated in 
autosomal dominant polycystic kidney disease (ADPKD) and tuberous sclerosis complex 
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(TSC), the function of the gene products, and mammalian target of rapamycin (mTOR) 
signaling as an important player in the pathogenesis of ADPKD and hamartomatous 
diseases. ADPKD, a potentially lethal monogenic disorder with an estimated prevalence of 
1:400 to 1:1000, is characterized by the development of cysts in the kidneys, liver, seminal 
vesicles, pancreas, and arachnoid membrane; intracranial aneurysms and dolichoectasias; 
aortic root dilation and aneurysms; mitral valve prolapse; and abdominal wall hernias (1). 
TSC, an autosomal dominant disease with a prevalence of 1:6000 to 1:10,000, is 
characterized by multiple brain, retina, skin, kidney, heart, and lung hamartomas (2). A 
Portuguese family segregating a chromosome 16:22 translocation with ADPKD and TSC 
helped to identify the TSC2 and PKD1 genes immediately adjacent to each other on 
chromosome 16 (3,4). The cloning of PKD1 and subsequently PKD2, genes that encode 
polycystin-1 and polycystin-2, led to the identification of a new subfamily of transient 
receptor potential channels (5). The cloning of TSC1 and TSC2, genes that encode hamartin 
and tuberin, made possible studies of Tsc1 and Tsc2 homologues in Drosophila and the 
subsequent identification of the hamartin-tuberin heterodimer as a GTPase-activating protein 
for Rheb (Ras homolog enriched in brain), linking growth factor, nutrient, and energy 
sensing signals to mTOR and mTOR-dependent targets (6). The description of a contiguous 
gene syndrome characterized by early onset of severe polycystic kidney disease (PKD) in 
patients with deletions involving PKD1 and TSC2 suggested that polycystin-1 and tuberin 
function in a common pathway (7). A better understanding of the molecular mechanisms 
laid out the foundation for the development of potentially effective therapies (8). The 
purpose of this review is to critically analyze the potential benefits and risks of mTOR 
inhibitors to treat ADPKD, TSC, and other hamartomatous diseases.
Overview of mTOR Signaling and Inhibitors
mTOR is a serine/threonine kinase of the phosphoinositide 3-kinase (PI3K)-related kinase 
family identified as the mammalian target of rapamycin (sirolimus). Rapamycin is a fungal 
metabolite found to have potent growth-inhibitory and immunosuppressant properties (9,10).
mTOR is the core component of two distinct complexes only partially characterized: 
complex 1 (mTORC1) and complex 2 (mTORC2) (9). In addition to mTOR, both complexes 
contain the small adaptor GβL but differ in the composition of additional adaptors. In 
particular, the presence of the Rictor protein in the complex characterizes mTORC2, 
whereas the Raptor protein defines mTORC1 (Figure 1, A and B) (10–12). mTOR can be 
specifically inhibited by rapamycin only when it is in mTORC1, leading to the initial 
definition of mTORC1 as “rapamycin sensitive” and of mTORC2 as “rapamycin insensitive” 
(12), although subsequent studies demonstrated that the mTORC2 assembly can be inhibited 
in long-term treatments with rapamycin in some cell types (13).
The functions and downstream biologic effects of the two complexes are also different. 
mTORC1 is involved in regulating cell cycle progression, translational control, and cellular 
energy responses (11), whereas mTORC2 has been recently identified as the kinase 
responsible for phosphorylating Akt (or protein kinase B) in Ser-473 and plays a role in 
regulating the actin cytoskeleton (12,14).
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mTORC1 is activated in response to an elevated GTP-bound form of Rheb, a small GTPase 
of the Ras superfamily, through an unclear mechanism (15). The guanine nucleotide 
exchange factor inducing Rheb’s active state was recently identified in Drosophila (16), 
whereas the GTPase-activating protein (GAP) inducing its inactive state is tuberin, the TSC2 
gene product (17). The mechanisms regulating the complex TSC1/TSC2 have been the focus 
of intense investigations, leading to the identification of several cascades that regulate the 
GAP activity of TSC2, and consequently Rheb/mTORC1 (Figure 2). Tuberin can be 
phosphorylated in numerous phosphosites (18). Several kinases have been reported to 
phosphorylate tuberin; some of them lead to inhibition of its GAP activity, ultimately 
resulting in upregulation of mTORC1, including Akt (19), p90RSK (20), and the 
extracellular-related kinases (ERKs) (21), whereas others lead to enhanced GAP activity, 
ultimately resulting in downregulation of mTORC1, including 5′-AMP-activated protein 
kinase (AMPK) (22), GSK3β (23), and the hypoxia-induced molecule REDD1 (24).
The two effectors of mTORC1 that are better characterized are the ribosomal S6 kinases 
(SK6; p70S6K1 and p70S6K2) and the eukaryotic initiation factor 4 binding proteins 1 and 
2 (4E-BP1 and 4E-BP2) (9,10). S6K is activated by phosphorylation at several sites, but the 
one with highest sensitivity to rapamycin and thus believed to be a direct target of mTORC1 
is threonine 389 (25). Upon activation, S6K phosphorylates subunit 6 of ribosomal protein, 
leading to a general activation of translation through an unclear and still highly debated 
mechanism (9,10). Phosphorylation of 4E-BP instead leads to dissociation from eukaryotic 
initiation factor 4E, which is released, allowing the formation of translation initiation 
complexes (9,10). Thus, both branches of the downstream effectors of mTORC1 regulate 
translation and growth (size) of cells (Figure 1C).
In addition to acting on subunit 6 of ribosomal protein, S6K was recently found to regulate a 
feedback loop toward the PDGF receptor and the insulin receptor substrate (IRS) (26,27). 
Upon phosphorylation in Ser/Thr, IRS undergoes degradation (28), thus attenuating the 
response to insulin and the activation of PI3K/Akt and Ras/ERKs (29,30). As a result of this 
effect, a feedback loop is initiated whereby activation of mTORC1 results in activation of 
S6K, which in turn downregulates the IRS, PI3K/Akt, and Ras/ERKs, thus diminishing their 
effect on the TSC1/TSC2 complex and ultimately restoring the basal activity of mTORC1. 
Because of these feedback loops, constitutive inhibition of mTORC1 ultimately results in 
upregulation of PI3K/Akt and Ras/ERK pathways (29,30). It is important to consider this 
when designing therapeutic approaches through the inhibition of mTORC1.
As outlined above, mTOR was identified as the target of rapamycin and subsequently shown 
to be specifically inhibited by this metabolite. Rapamycin and its subsequent derivatives 
CCI-779 (temsirolimus), RAD001 (everolimus), and AP23573 (deforolimus) all share a 
similar chemical structure and comprise a binding site for the intracellular immunophilin 
FKBP12 (31). Interaction with FKBP12 is an absolute requirement for rapamycin and its 
derivatives to bind to and inhibit mTOR (31). Whereas the mechanism of action for all of 
these drugs is similar, the different chemical composition renders the rapamycin derivatives 
soluble in water, allowing for intravenous or oral administration (31). All of these molecules 
are specific for inhibition of mTOR only when it is associated with mTORC1. In certain 
cases, this might represent a problem, because inhibition of mTORC1 leads to upregulation 
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of tumorigenic cascades (e.g., PI3K/Akt and Ras/ERKs) as highlighted above. Although 
long-term treatment with rapamycin was reported to downregulate mTORC2, this effect 
appears to be cell-type-dependent (13). Therefore, treatment with rapamycin will be 
effective and safe mostly in tissues (cancers or cystic tissues) in which mTORC2 is inhibited 
in long-term treatments. A new generation of drugs directed against the mTOR catalytic site 
is being developed that might be effective on mTORC1 and mTORC2 (32). These drugs will 
be preferable in cases where the feedback loops are insensitive to long-term treatment with 
rapamycin. Alternatively, combination therapies might be used to bypass this problem 
(33,34).
Dysregulation of mTOR Signaling in Hamartoma Syndromes
Hamartomas are a benign, histologically defined subtype of tumors with relatively normal 
differentiation but disorganized tissue architecture. Hamartomas can present as incidental 
findings in the general population or clinically defined familial syndromes with variable 
expressivity involving one or more body sites. Positional cloning of Mendelian hamartoma 
syndromes has identified at least seven disease genes (TSC1, TSC2, PTEN, STK11, FLCN, 
PKD1, and NF1) that encode components of multiple signaling pathways that converge at 
the mTORC1 complex (Figure 3, Table 1). Although an autosomal dominant inheritance 
underlies all of these syndromes, a “2-hit” cellular recessive mechanism has been shown in 
many but not all of the associated hamartomas, suggesting that the disease genes function as 
tumor suppressors (35,36). Interestingly, some but not all of these mTOR-dysregulated 
hamartoma syndromes are associated with an increased risk of cancer (35,37,38).
Figure 3 shows the components of the key signaling pathways that converge at the 
rapamycin-sensitive mTORC1 and how disease mutations affecting some of the upstream 
regulatory proteins can lead to mTOR activation. In this regard, the most extensively 
characterized example is TSC (35,39). The TSC1-TSC2 protein complex serves as a node 
that integrates cues from growth factors, nutrients, and other external signals to regulate 
mTORC1 activity. Loss-of-function TSC1 or TSC2 mutations are associated with increased 
Rheb-GTP levels and aberrant activation of mTORC1 in various TSC-associated 
hamartomas (39,40). Growth factor stimulation and increased Akt activity, after receptor 
tyrosine kinase activation, provide a major upstream negative regulatory signal to TSC2. 
Loss-of-function mutations of phosphatase and tensin homolog, a lipid phosphatase that 
negatively regulates Akt, have been documented in several closely related clinical 
syndromes linked to aberrant mTOR activation (41,42). Similarly, growth factors that lead to 
RAS activation can also provide an upstream negative regulatory signal to TSC2 through the 
mitogen-activated protein kinase (ERK/RSK) cascade. Loss-of-function mutations of 
neurofibromin, which negatively regulates RAS, can cause aberrant mTOR activation in 
neurofibromatosis (43). By contrast, cellular energy depletion (low AMP) is sensed by 
AMPK and provides a positive regulatory signal to TSC2. Loss-of-function mutations of 
STK11 (LKB1), which release TSC2 activation by AMPK, cause Peutz-Jeghers syndrome 
and aberrant mTOR activation (44). Likewise, through a complex, incompletely understood 
interaction between folliculin (FLCN), FLCN-interacting protein 1, and AMPK, loss-of-
function mutations of FLCN, the product of a gene that is mutated in Birt-Hogg-Dubé 
(BHD) syndrome, have also been shown to cause aberrant mTOR activation (45,46). More 
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recently, aberrant mTOR activation has been implicated in playing a pathogenic role in 
ADPKD (see later section) (47).
The documentation of aberrant mTOR activation in the above hamartoma syndromes 
provides a strong rationale for testing the therapeutic efficacy of mTOR inhibitors in these 
disorders. Indeed, a recently completed nonrandomized, open-label study of 20 patients with 
TSC showed that a 12-month treatment with rapamycin reduced the mean volume of renal 
angiomyolipomas by approximately 50% compared with the baseline value and improved 
the lung function of 14 of the same patients who also have lymphangioleiomyomatosis. 
However, the renal and pulmonary treatment benefits tended to reverse in most patients after 
discontinuation of rapamycin for 1 year (48). Despite these exciting initiatives, a better 
understanding of the pathobiology of mTOR signaling in the above hamartoma syndromes is 
needed if the therapeutic potential of mTOR inhibitors in these disorders is to be fully 
exploited. For example, what are the molecular bases for the distinct phenotypic differences 
and tissue specificities in these disorders? Does mTORC2 play a role in their pathobiology 
(37)? Is ciliary dysfunction involved in their pathogenesis (38)? Why is there an increased 
risk for cancer in some but not all of these disorders (Table 1)? Several groups have begun to 
address this latter question by suggesting that hyperactive mTOR signaling activates crucial 
negative feedback mechanisms through S6K (Figure 3) (27,49) or PDGF receptor-mediated 
(26) downregulation of IRS, PI3K, and Akt activities. This may explain why the risk of 
cancer is not increased in ADPKD, but is increased in phosphatase and tensin homolog-
associated hamartoma syndromes. However, this negative feedback mechanism should also 
operate in neurofibromatosis, Peutz-Jeghers, and BHD syndromes, all of which are 
associated with an increased risk of cancer (43,44,46).
mTOR Signaling in PKD
The earliest suggestion for a role of mTOR in PKD came from the observation that many 
TSC patients develop renal cysts. The PKD1 and TSC2 genes were found to lie immediately 
adjacent to each other on chromosome 16 (3,50) in a tail-to-tail orientation, and this gene 
proximity is highly conserved from humans to fish (51), suggesting that the gene products 
may be functionally linked or that their expression may at least be coregulated. In 
approximately 2% to 3% of TSC patients, a contiguous germline deletion that affects TSC2 
and PKD1 leads to much earlier onset and more severe PKD than mutations in the individual 
genes (7). Thus, the gene products may function in a common pathway, and the severe cystic 
phenotype in patients with a combined TSC2 and PKD1 mutation may be due to gene 
dosage that affects two components of the same pathway.
Components of the mTOR pathway (mTOR, S6K, and S6) were found to be aberrantly 
phosphorylated in epithelial cells of a subset of renal cysts in human ADPKD, autosomal 
recessive PKD, and PKD mouse models (38,47,52,53). The observation that some but not all 
of the cysts exhibit signs of mTOR activation suggests that this pathway may only be active 
during certain stages of cyst development or that other signaling pathways may be required 
for full mTOR activation. It is currently unclear if mTOR activation is sufficient to induce 
cyst formation because renal cysts are observed in only 32% of TSC patients and in most 
cases the cystic disease is relatively mild (54). These observations suggest that mTOR 
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activation may be important, but not sufficient, for cyst growth. However, several groups 
independently found that rapamycin reduced renal cyst growth in rodent models of PKD 
(see below).
The mechanism for mTOR activation in ADPKD must ultimately be due to a direct or 
indirect mechanistic link to the polycystins. The identification of a binding interaction 
between the cytoplasmic tail of PC1 and tuberin (47) supports a model in which PC1 
normally suppresses mTOR activity by its interaction with tuberin (47,55,56). Recently, 
Pkd1−/− mouse embryonic fibroblasts were shown to have increased cell size and 
phosphorylation levels of S6K, S6, and 4EBP1, consistent with activation of mTORC1 (57). 
Conversely, PC1 overexpression reduced ERK activation and S6KThr389, S6, and 4EBP1 
phosphorylation, despite strong Akt activation. Additional studies using MDCK cells 
expressing dominant negative or constitutionally active Akt or MEK constructs confirmed 
that PC1 downregulates cell size and mTORC1 activation by affecting the ERK-mediated 
phosphorylation of tuberin at S664. Clinical studies have demonstrated high levels of 
constitutively active ERK in TSC-associated lesions that lack loss of heterozygosity in the 
TSC genes and in TSC2+/− cell lines (58), which suggests a positive feedback loop, with 
ERK activation not only upstream but also downstream of TSC/mTOR.
Currently, the role of Akt in mTOR regulation and cell proliferation in PKD remains unclear. 
In normal renal cells, Akt phosphorylates an inhibitory site on B-Raf, preventing cAMP 
activation of the B-Raf/MEK/ERK signaling pathway and cell proliferation (59–61). In 
cultured cells from human ADPKD cysts, Akt activity is reduced, and cAMP activates B-
Raf signaling to the MEK/ERK pathway and cell proliferation (60). On the other hand, 
phosphorylated Akt (p-Akt) was found to be elevated in mitotic cells in Cy/+ kidneys (62). 
The reason for the discrepancy in basal Akt activity between cultured human ADPKD cells 
and cyst cells of Cy/+ kidneys in vivo is unclear. It is possible that Akt may modulate 
mTORC1 activity independent of its inhibitory effect on B-Raf.
mTOR is active in renal epithelial cells in developing, postnatal kidneys of mice, but 
markers such as P-mTOR and P-S6 become almost undetectable in adult kidneys (46) 
(Shillingford and Weimbs, unpublished results). This, and the finding that high-level 
rapamycin treatment had no apparent structural or functional effects on the healthy, adult 
mouse or rat kidney (47,63,64), suggests that mTOR activity is not needed for normal renal 
function. By contrast, increased cell proliferation, fibrosis, and cellular hypertrophy after 
renal injury (e.g., ischemia/reperfusion and ureteral obstruction) and during compensatory 
hypertrophy after unilateral nephrectomy are largely inhibited by rapamycin treatment (64–
67). These studies suggest that activation of the mTOR pathway is an essential, but normally 
dormant, component of the response to renal injury (64–67). It has been suggested that the 
changes leading to renal cyst growth in PKD represent the aberrant activation of a renal 
repair pathway (55,56). Given that the PKD rodent models that exhibit activated mTOR 
and/or respond to mTOR inhibition involve a wide variety of affected proteins (Table 2), it 
has been suggested that all of these proteins (and likely many more) function in pathways 
that eventually converge on the mTOR pathway (55,56). Such a convergent pathway 
represents a highly attractive therapeutic target.
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Efficacy of mTOR Inhibitors in PKD Rodent Models
In all PKD rodent models tested so far, treatment with mTOR inhibitors has proven effective 
in inhibiting cyst growth and kidney enlargement and preserving renal function (Table 2). In 
the Cy/+ rat, a mutation in Anks6 (formally Pkdr1) that encodes for SamCystin, a novel 
protein with no known function, causes slowly progressive cystic disease (68). 
Administration of 0.2 mg/kg per d rapamycin by intraperitoneal injection for 5 weeks (69), 
or 2 mg/kg per d orally for 8 to 12 weeks (70,71), reduced PKD progression and preserved 
renal function (69,70). Everolimus, a rapamycin analogue, proved equally effective in the 
Cy/+ rat (72). Long-term rapamycin treatment from 1 to 12 months resulted in a 
normalization of kidney volume, renal function, blood pressure, and heart weight (73).
The orpk-rescue mouse arose from alterations of the gene encoding for Polaris, a protein 
involved in ciliogenesis and intraflagellar transport, leading to slowly progressing PKD (74). 
Treatment with rapamycin for 1 month (5 mg/kg per d, intraperitoneally) resulted not only in 
inhibition of renal growth but significant regression of already enlarged kidneys, as 
determined by magnetic resonance imaging (47). This was likely due to the observed 
induction of apoptosis, specifically in cystlining cells. In the same study, the effect of 
rapamycin was tested in the bpk mouse, a rapidly progressive PKD model caused by a 
mutation in bicaudal-C, an RNA-binding protein of no known function in mammals. 
Rapamycin treatment for 2 weeks (1.67 or 5 mg/kg per d, intraperitoneally) was highly 
effective in slowing renal and cyst growth and preserving renal function (47).
The pcy gene in mice is orthologous to the NPHP3 gene in humans; mutation in human 
NPHP3 causes adolescent nephronophthisis (75). Phosphorylated S6K was slightly elevated 
at 4 weeks, moderately increased at 12 weeks, and markedly increased at 30 weeks of age, 
whereas phosphorylated ERK was uniformly increased at all ages (76). Administration of 
pellets releasing rapamycin from 20 to 30 weeks of age to male pcy mice at a rate of 3 
mg/kg per d prevented further renal cystic enlargement and deterioration of renal function 
(76). However, treatment between 6 and 12 weeks of age was without detectable effect, 
suggesting that mTOR activation may be less important at early stages of cystic disease in 
this animal model (76). Rapamycin was also protective in female pcy mice treated from 18 
to 28 weeks of age (77).
Recently, rapamycin was tested in a cystic mouse model generated by a kidney-specific 
knockout of BHD, a gene that encodes FLCN (46). FLCN is the protein affected in BHD 
syndrome (78) and has been implicated in the regulation of the AMPK/mTOR pathway, 
although its exact function is unclear (79). These mice exhibit rapidly progressing PKD and 
die from renal failure by 3 weeks (46). Rapamycin treatment (2 mg/kg per d, 
intraperitoneally) reduced renal growth and nearly doubled the life span of the mice (46).
Finally, mTOR inhibitors have been recently tested in animal models orthologous to human 
ADPKD. Rapamycin treatment (5 mg/kg per d, intraperitoneally) was highly effective in a 
newly developed mouse model in which the Pkd1 gene was inactivated in a mosaic fashion 
(80). Rapamycin treatment resulted in strong inhibition of renal cyst growth, partial reversal 
of the cystic phenotype in already enlarged kidneys, and preservation of renal function. 
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Rapamycin (1.5 mg/kg per d, intraperitoneally) significantly reduced the liver/body weight 
ratio, liver cyst volume, and pericystic microvascular density in a conditional Pkd2 knockout 
mouse (81). In both studies, rapamycin reduced the rates of cell proliferation while 
enhancing the rates of apoptosis. These would suggest that mTOR inhibition may also be 
effective in human ADPKD.
Preclinical studies summarized in Table 2 indicate that mTOR inhibition may provide a 
potential clinical approach to slow the progression of PKD; however, several limitations to 
these studies should be considered. The doses of rapamycin or everolimus used in rodent 
studies exceed the dose commonly used for immunosuppression in patients. In rodents, high 
doses of mTOR inhibitors appear to be well tolerated with no adverse effects. Small 
reductions in body weight have been reported in some studies (69,71,73) but not others 
(76,82). Rapamycin at 3 mg/kg per d (intraperitoneally) was needed to achieve complete 
suppression of S6 phosphorylation in the brain of an epilepsy mouse model with conditional 
inactivation of the TSC1 gene (82). To our knowledge, the dose of mTOR inhibitor required 
to adequately suppress mTOR in target organs, including PKD kidneys, in humans is 
unknown.
Retrospective Clinical Studies of mTOR in ADPKD
Some ADPKD patients who undergo renal transplantation receive rapamycin for immune 
suppression. This has led to the fortuitous circumstance in which some ADPKD patients 
with their native polycystic kidney still in place have been treated with rapamycin. It was 
reported in a small retrospective study that the total renal volumes decreased by 
approximately 25% during an average period of 2 years in transplanted ADPKD patients 
who were treated with rapamycin, whereas no significant change was found in the 
nonrapamycin control group (47). In a subsequent larger study, a similar trend was observed, 
but the difference from the control group did not achieve statistical significance (83). 
However, there was a significant reduction in the total liver volumes, whereas the liver 
volumes increased in the control group (83). These results are encouraging because they 
suggest that the dose of rapamycin required for immunosuppression may be sufficient to 
suppress mTOR activity and the growth of liver and kidney cysts. An important caveat in 
these studies is that the kidneys of these patients represent highly cystic end-stage kidneys in 
which little, if any, normal renal tissue remains.
mTOR, Fibrosis Chronic Kidney Disease, and Animal Models of Noncystic 
Renal Disease
mTOR signaling is important in the regulation of intrinsic renal cell, T cell, and B cell 
proliferation and function. Therefore, it is not surprising that activation of mTOR has been 
implicated in the progression of chronic kidney disease (CKD), a common pathology of 
glomerulosclerosis and tubulointerstitial fibrosis initiated by many diverse causes of renal 
injury. mTOR inhibition can be beneficial or deleterious depending on the nature and 
severity of the underlying renal injury, timing of treatment in relation to the onset of disease, 
and dose of mTOR inhibitor.
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Akt and/or mTOR are activated or play a role in nonimmunologic models of CKD, such as 
5/6 nephrectomy (84,85), chronic ischemic nephropathy (86–88), unilateral ureteral 
obstruction (89,90), type I (streptozotocin-induced) (85,91–93) and type II (db/db mice and 
Zucker rat) (94,95) diabetic nephropathy, protein overload (96), and adriamycin- and 
puromycin-induced nephropathies. In all of these cases, administration of rapamycin 
inhibited the development and progression of the disease at least in part by inhibiting 
inflammation (87) and the expression of fibrosis-associated genes such as TGF-β (67,86,97). 
Of note is that whereas mTOR inhibition early after renal mass reduction caused further 
reduction in renal function (84), late treatment was protective (84). Similarly, mTOR 
inhibition delayed recovery from renal ischemia reperfusion injury in mice (98,99) and rats 
(64,100,101) and aggravated protein ovesrload nephropathy (96), whereas it had a beneficial 
effect on chronic ischemic nephropathy induced by ischemia-reperfusion injury. These 
observations indicate that mTOR inhibition may interfere with adaptive increases in renal 
proliferation that are necessary for recovery from injury but inhibit potentially deleterious 
aspects of injury repair such as development of inflammation and fibrosis.
Interestingly, Rangan and Coombes (102) found that mTOR inhibition attenuates the renal 
enlargement in adriamycin nephropathy and the fibrosis without reducing proteinuria in rats, 
whereas Lui et al. (103) found that rapamycin given at the time adriamycin nephritis was 
induced or started 1 week after induction was effective in reducing the proteinuria, 
interstitial inflammation, and collagen expression. Everolimus pretreatment in puromycin 
aminonucleoside nephrosis similarly ameliorated the puromycin aminonucleoside-induced 
proteinuria and mononuclear leukocyte infiltration in mice (104). The attenuation of 
adriamycin- and puromycin-induced nephropathies contrasts with other reports that mTOR 
inhibitors impair pathways essential for podocyte integrity and predispose to glomerular 
injury (see below) (105,106).
The mTOR pathway also affects the development and progression of immunologically 
mediated forms of CKD, such as membranous glomerulopathy (passive and active forms of 
Heymann nephritis) (65,107), mesangiocapillary anti-Thy-1 nephritis (108,109), lupus (105–
107,110,111), and antiglomerular basement membrane GN (112). Whereas mTOR inhibitors 
usually exert beneficial effects consistent with their immunosuppressive and anti-
inflammatory actions, they can be detrimental under certain conditions because of 
downregulation of vascular endothelial growth factor (VEGF). For example, administration 
of high-dose everolimus to rats early after “full-dose” anti-Thy-1 antiserum inhibits 
endothelial cell (EC) proliferation and increases apoptosis, crescent formation, 
glomerulosclerosis, and mortality, whereas low-dose everolimus or treatment of a less severe 
lesion (“reduced dose” anti-Thy-1 model) is relatively safe, and late treatment (after the 
acute proliferative phase) inhibits glomerular hypertrophy, glomerulosclerosis, proteinuria, 
and interstitial fibrosis and improves renal function (108,109). On the other hand, rapamycin 
significantly reduces B and T cell responses and protects from GN when administered early 
in the autologous phase of antiglomerular basement membrane GN, but it worsens GN by 
disturbing the EC/VEGF system in the kidney once disease is established (112).
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Role of mTOR in Vascular Remodeling and Angiogenesis in ADPKD
The polycystins are strongly expressed in endothelial and vascular smooth muscle cells 
(VSMCs) (113–116). VSMCs from Pkd1+/− or Pkd2+/− mice exhibit an exaggerated 
contractile response to phenylephrine associated with lesser cytosolic calcium rise 
(117,118). ECs from Pkd1 null mice lacking polycystin-1 in primary cilia cannot modulate 
calcium signaling and nitric oxide synthesis in response to fluid shear (119). Endothelium-
dependent vasorelaxation is reduced in ADPKD (120). Therefore, it is not surprising that 
vascular pathology constitutes a prominent component of this disease. This includes renal 
(vascular remodeling, rarefaction, angiogenesis) and extrarenal [arterial aneurysms, 
dolichoectasias, and dissections (121), and possibly an increased risk for cerebral vasospasm 
(122) and atherosclerosis (123)] vascular pathologies.
The renal vasculature in ADPKD is characterized by small artery and arteriolar sclerosis, 
rarefaction, and angiogenesis at relatively early stages of the disease (121,124–128). These 
are not distinct, but are interrelated processes. Sustained vasoconstriction and increased 
blood pressure induce arterial/arteriolar hyperplasia and sclerosis, rarefaction, and focal 
ischemia (129). Ischemia through hypoxia-inducible transcription factors upregulates VEGF 
and other growth factors that stimulate angiogenesis (130). VEGF, normally expressed in 
tubular epithelia, is overexpressed in cyst epithelial cells (128,131). Inflammatory mediators 
in cyst fluids may contribute to the upregulation of VEGF (132), which in a paracrine 
fashion further stimulates angiogenesis and further cyst growth (131).
The PI3K/Akt/mTOR signaling pathway plays an important role in the vascular smooth 
muscle changes that occur in ADPKD. VSMC plasticity is important for pathologic 
responses such as intimal hyperplasia and atherosclerosis (133). These require 
dedifferentiation of VSMCs from a contractile to a proliferative, migratory, synthetic 
phenotype. Activation of mTOR effector S6K1, feedback inhibition of IRS-1, and inhibition 
of Akt2 mediate this phenotypic switch (134). Rapamycin blocks this pathway, promotes the 
differentiated contractile phenotype, inhibits VSMC migration and proliferation, and 
attenuates intimal hyperplasia. Consistent with these effects, inhibition of mTOR markedly 
reduces transplant vasculopathy in recipients of cardiac (118) and renal transplants (135) and 
the incidence of restenosis, although improving coronary artery physiology after rapamycin-
eluting stents (136–139). Therefore, mTOR inhibitors have the potential of attenuating the 
renal vascular remodeling and possibly early development of atherosclerosis associated with 
ADPKD.
Both mTORC complexes and Akt signaling play a key role in angiogenesis (140–143). 
mTORC1 activates EC proliferation. mTORC2 directly phosphorylates Akt and promotes 
EC survival (13,144). Akt activates endothelial nitric oxide synthase by direct 
phosphorylation (145). Akt1, rather than Akt2, is required for acute permeability response to 
VEGF and angiogenesis in a hind-limb ischemia model (146). Contrary to VSMCs, where 
Akt is only partially inhibited after prolonged treatment with mTOR inhibitors, Akt is 
strongly inhibited in ECs after exposure to rapamycin for 24 hours (140). These effects on 
ECs and VSMCs may contribute to the increased risk of late coronary artery thrombosis and 
peri-stent coronary aneurysms with rapamycin-eluting stents (140,147–150).
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Angiogenesis is required for tumor growth, and the antineoplastic action of mTOR inhibitors 
is due at least in part to their antiangiogenic properties (151,152). Capillary sprouting and 
development of a rich vascular network around the cysts ensures that the proliferation of 
epithelial cells is matched by an adequate supply of blood and nutrients (127). Therefore, 
mTOR inhibition has the potential of preventing cyst expansion by its antiangiogenic effect 
(127). However, the results of antiangiogenic strategies targeting VEGF in PKD have been 
mixed. Treatment of Han:SPRD Cy/+ rats with ribozymes inhibiting mRNA expression of 
VEGF receptors 1 or 2 blunted cystogenesis and improved renal function (131). 
Administration of the VEGF receptor inhibitor SU-5416 to Pkd2WS25/− mice was protective 
against the development of cystic disease in the liver, but not in the kidney (153). On the 
other hand, treatment of developing CD-1 mice with antibodies against VEGF receptor 2 
promoted renal cyst growth (154).
Strategies targeting angiogenesis in ADPKD raise additional concerns. Apoptotic EC loss in 
peritubular capillaries is associated with interstitial fibrosis (155–157). By further inducing 
EC apoptosis, such strategies could potentially accelerate the development of interstitial 
fibrosis, a prominent feature in polycystic kidneys (124), and hasten the decline in kidney 
function. EC and VSMC apoptosis may be important in the pathogenesis of arterial 
aneurysms and dissections, well recognized extrarenal manifestations of ADPKD. However, 
to date, no association between administration of mTOR inhibitors and aneurysmal rupture 
or arterial dissection has been reported. By their effects on nitric oxide production and 
VSMC contractility, mTOR inhibitors could enhance the development of hypertension or 
vasospastic complications. Although hypertension has been reported to be less common in 
mTOR than in calcineurin inhibitor-treated patients, a recent study has shown an equivalent 
development of hypertension in rats treated with mTOR or calcineurin inhibitors (158). 
Hypertension, proteinuria, and acute kidney injury are recognized adverse effects of anti-
VEGF therapy (159).
Risk/Benefit Considerations for mTOR Inhibition Therapy: Lessons Learned 
from Organ Transplantation and Treatment of Glomerulopathies
mTOR inhibitors have gained a proper place in the present-day immunosuppressive 
armamentarium in renal transplantation (160–162). However, significant adverse events lead 
to discontinuation of mTOR inhibitors in between 7% and 37% of patients, with 
discontinuation reported to be directly related to exposure to sirolimus and tacrolimus (7.8% 
and 2.2%, respectively) (163,164). Nonrenal-related side effects are listed in Table 3. These, 
along with a mild to moderate nephrotoxic potential (see below), need to be kept in mind 
when considering the use of mTOR inhibitors for nontransplant and nonmalignant medical 
disorders such as ADPKD.
The mTOR inhibitor-induced dyslipidemia may result in part from a decrease in catabolism 
of apolipoprotein (apo)B100-containing lipoproteins, possibly because of downregulation of 
LDL receptors (165,166). This hyperlipidemic effect should be weighed against the potential 
antiatherogenic effects of these drugs. Administration of everolimus to LDL receptor-
deficient (LDLR−/−) mice markedly reduced the extent of atherosclerosis despite a 40% 
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increase of plasma cholesterol (167). Although administration of rapamycin to transplant 
recipients increases cholesterol and triglyceride levels by 17 and 59 mg/dl (at a dose of 2 
mg/d) or by 30 and 103 mg/dl (at a dose of 5 mg/d), respectively, compared with patients 
receiving placebo or azathioprine, and the Framingham risk model predicts that a 17-mg/dl 
elevation in cholesterol would increase the incidence of coronary heart disease by 1.5 new 
cases per 1000 persons per year and coronary heart disease death by 0.7 events per 1000 
persons per year (168), no increase in the 4-year risk of cardiovascular events was detected 
in rapamycin-treated patients in a single-center study (169).
Of particular concern is their potential nephrotoxicity. In transplant patients, mTOR 
inhibitors cause delayed renal allograft function and increase the nephrotoxicity of 
calcineurin inhibitors. On the other hand, conversion from calcineurin to mTOR inhibitor-
based immunosuppressive regimens offers the opportunity to improve renal function (170). 
The probability of benefit from this conversion diminishes with time from transplant, 
impairment of renal function, and severity of proteinuria (170,171). A large, multicenter, 
prospective, randomized, open-label rapamycin renal conversion trial (CONVERT) 
randomly assigned (2:1) 830 maintenance renal allograft recipients (stratified by baseline 
GFR; 20 to 40 versus >40 ml/min) to undergo conversion or to continue receiving 
calcineurin inhibitor-based therapy (172). Enrollment in the group with baseline GFR of 20 
to 40 ml/min was discontinued because of a higher incidence of safety end points in the 
rapamycin conversion arm (16.7% versus 0%). In the patients with baseline GFR >40 
ml/min and urine protein to creatinine ratio ≤0.11, a modest improvement in GFR was noted 
at 12 and 24 months. De novo proteinuria occurred as an unexpected finding after sirolimus 
conversion, and worsening proteinuria was associated with sclerotic glomeruli at baseline 
(172). A smaller study assessed outcomes by the magnitude of proteinuria at conversion 
(≤300, 301 to 3500, or >3500 mg/d). Increasing degree of proteinuria at baseline was 
associated with increased levels of creatinine 6 months later (173). Similar observations have 
been made in cardiac and pulmonary transplant patients (174,175).
The electrophoretic pattern, response to angiotensin-converting enzyme inhibitors, and 
demonstration of normal tubular endocytosis of albumin indicate that the proteinuria 
associated with the administration of mTOR inhibitors is of glomerular origin (176–178). 
Development of or increase in proteinuria after switching from a calcineurin to an mTOR 
inhibitor may in part be due to a renal hemodynamic effect (105). Nevertheless, a large body 
of evidence indicates that mTOR inhibitors are, at least in part, directly responsible. 
Development or increase in proteinuria has been observed in patients switched to rapamycin 
from an azathioprine-based regimen (179), in kidney transplant recipients treated de novo 
with mTOR inhibitors compared with control groups receiving calcineurin inhibitor-based 
(180–182) or mycophenolate-based (183) immunosuppressive regimens, and rarely in liver 
transplant recipients (184). In a few patients, proteinuria was in the nephrotic range and 
remitted after withdrawal of the drug (185). Prolonged rapamycin treatment of cultured 
human podocytes reduces the expression of total mTOR, mTORC1 activation, Rictor, 
mTORC2 formation, and Akt phosphorylation; downregulates nephrin, TRPC6, Nck, WT-1, 
and VEGF; and inhibits cell adhesion and motility (105,106).
Torres et al. Page 12
Clin J Am Soc Nephrol. Author manuscript; available in PMC 2017 September 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
There is limited information on the use of mTOR inhibitors in nontransplanted patients with 
underlying renal disease. Administration of rapamycin to patients with focal segmental 
glomerulosclerosis or proteinuric primary glomerulopathies has been associated with effects 
ranging from worsening of proteinuria and/or acute kidney injury (186,187) to partial or 
complete remission of the proteinuria in some patients (188). Proteinuria (1 to 7 g/d) or 
microalbuminuria developed in 3 and 5 of 62 type I diabetes mellitus patients, respectively, 
who underwent islet transplantation; in all patients, the proteinuria or microalbuminuria 
resolved after discontinuation of rapamycin (189). Proteinuria in ADPKD is usually low 
grade (<1 g/d) and associated with higher disease severity and worse prognosis (190–192). 
Currently, there is no information on whether administration of mTOR inhibitors to patients 
with ADPKD might increase proteinuria or negatively affect renal function, although it 
appeared to be safe in an animal model of PKD (76,193). Therefore, close monitoring of 
proteinuria and renal function is essential in clinical trials of mTOR inhibition in ADPKD, 
particularly in patients with more advanced stages of the disease.
Strategies for a Clinical Trial Design Using mTOR Inhibitors in ADPKD
Data from various longitudinal ADPKD cohort studies have demonstrated that cyst volume 
growth represents an exponential expansion process (194–196). These studies have also 
impressively shown that the GFR decline occurs only late in the disease, at a time when the 
kidney has already been irreversibly damaged by the relentlessly progressing cyst growth. 
The process of glomerular hyperfiltration might explain this dissociation between the 
steadily progressing cyst growth and the late GFR decline. The tardy decline of GFR is often 
accelerated, leading to ESRD within only a few years.
Therefore, the cyst volume growth rate represents a more suitable study end point than GFR 
decline, because the effect of a drug on cyst growth can be precisely monitored by repetitive 
magnetic resonance imaging or computed tomography scanning with subsequent volumetry 
of the kidneys and/or the cysts. GFR decline is a late phenomenon, and it might be difficult 
to obtain a therapeutic benefit with mTOR inhibitors at this later stage. This is also 
illustrated by another genetic disease, namely Fabry disease, which is a lysosomal storage 
disease for which it has been shown that late treatment with recombinant α-galactosidase 
enzyme replacement in proteinuric patients with impaired GFR has little or no effect (197). 
ADPKD and Fabry disease require establishment of treatment that is early and lifelong to be 
effective. Health authorities must be convinced to use cyst volume growth retardation as a 
meaningful clinical end point because it is likely that it will also retard or even prevent the 
occurrence of ESRD. It can also be expected that drugs that reduce cyst volume growth will 
have an effect on other ADPKD-related morbidities, including delayed development of 
hypertension or less cyst bleeding.
ADPKD is a slowly progressing disease, requiring a long treatment time to detect 
meaningful effects of mTOR inhibitors on cyst volume growth retardation. Volume changes 
can reliably be detected in a short interval of 6 months (195); however, because 
approximately 10% to 20% of patients display volume regression within 6 months (because 
of the spontaneous rupture of cysts) (195), a much longer observation time is recommended. 
The dosage of the mTOR inhibitors must also be adapted to the specific side effect profile of 
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these drugs. Mucositis, infections, hyperlipidemia, anemia, and thrombocytopenia are the 
most common, and the severity of these side effects depends on the dosage and the achieved 
trough levels. Therefore, for a lifelong treatment, it would be desirable to use a lower dosage 
than what is used for prevention of transplant rejection.
Currently, there is detailed information on the design of four ongoing clinical trials using 
mTOR inhibitors in patients with ADPKD (198,199). The data from these studies are 
summarized in Table 4. Several other additional small trials have been reported at scientific 
meetings, some of which have been published in abstract form (data not shown). A small 
pilot study of rapamycin (1 mg/d orally for 6 months) has recently reported promising 
results, but extraordinarily high rates of renal enlargement, particularly in the control group, 
were observed (200).
Three of the four trials use kidney (cyst) volume change as the primary end point. The 
patient numbers and dosing ranges are quite different in the four trials. The SUISSE 
ADPKD study enrolled 100 patients and is using rapamycin at 2 mg/d for 18 months. A 
larger German study enrolled 400 patients and is using everolimus for 2 years at a higher 
dose. The Cleveland Clinic and the Bergamo studies involve a smaller patient population 
with a dose-finding strategy.
Definitive data from these four clinical trials will be available in 2010. Certainly, if an 
important beneficial effect of mTOR inhibitors is found, more detailed dosing strategies 
targeting early, intermediate, and late stages of the disease need to be tested in additional 
trials. In the case that only a moderate positive effect is found, future trials could seek to 
establish whether combination therapy of mTOR inhibitors, which primarily target cell 
proliferation, with drugs targeting fluid secretion, would improve therapeutic results.
Currently, it is too early to recommend that patients with ADPKD start treatment with 
mTOR inhibitors. The results of the ongoing studies must be awaited, and patients must be 
informed accordingly.
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Figure 1. 
Schematic overview of the mTOR complexes, mTORC1 and mTORC2, and of the feedback 
loop. (A) The rapamycin-sensitive mTORC1 comprises, in addition to the mTOR kinase, 
raptor, GβL, PRAS40, and DEPTOR. (B) mTORC2 contains Rictor, GβL, Protor, Sin, and 
DEPTOR. (C) mTORC1 regulates translation, cell size, and the cell cycle, as well as 
autophagy and cellular metabolism. mTORC2 regulates the cellular cytoskeleton. In 
addition, mTORC2 is the kinase responsible for phosphorylation of Akt in Ser473. 
Activation of mTORC1 results in regulation of a negative feedback loop through which S6K 
inhibits the insulin receptor signaling by phosphorylating and inducing degradation of the 
adaptor IRS. As a consequence, activation of mTORC1 downregulates PI3k/Akt and the 
ERKs, whereas inhibition of mTORC1 upregulates both cascades.
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Figure 2. 
Overview of the cascades converging on regulation of the TSC2 gene product tuberin. 
Downstream of the tyrosine kinase receptor (TKR) signaling, Akt, ERK, and p90RSK can 
all phosphorylate different residues of TSC2, resulting in inhibition of its GAP activity 
toward Rheb (right diagram). As a result, activation of TKRs results in activation of the 
mTORC1 cascade. Amino acids can also activate mTORC1 downstream of the TSC1/TSC2 
complex by acting directly on mTORC1. In contrast, REDD1, AMPK, and GSK3β act as 
energy or hypoxia sensors and are able to potently inhibit the mTORC1 cascade by 
enhancing the TSC1/TSC2 activity toward Rheb (left diagram). Wnts can activate the 
mTORC1 complex by inhibiting GSK3β.
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Figure 3. 
Multiple signaling (AMPK, Ras/ERK, PIK3) pathways converge at the TSC1-TSC2 
complex to regulate the rapamycin-sensitive mTORC1 activity, protein synthesis, and cell 
growth. Mutations of at least seven (blue) disease genes associated with Mendelian 
hamartoma syndromes have been linked to mTORC1 activation (see text for more details), 
providing a rationale for the potential therapeutic use of mTOR inhibitors in these disorders. 
4EBP1, initiation factor 4E binding protein; FNIP1, folliculin-interacting protein 1; NF1, 
neurofibromin 1; PTEN, phosphatase and tensin homolog; RSK, p90 S6K 1; STK11, serine/
threonine kinase 11 (also known as LKB1); TSC1, hamartin; TSC2, tuberin.
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Table 1
Familial hamartoma syndromes linked to mTOR dysregulation (39–48)
Gene Protein Protein Function Disease Clinical Features
TSC1 Hamartin (TSC1) Binding partner for TSC2 Tuberous sclerosis Hamartomas in skin, central 
nervous system, and heart; 
renal cysts and 
angiomyolipomas; 
lymphangiomyomatosis
TSC2 Tuberin (TSC2) Rheb GAP Tuberous sclerosis Same as above
PTEN PTEN 3′-phosphoinositide phosphatase PTEN-hamartoma tumor syndromes Hamartomas in multiple 
organs, lentigines, 
macrocephaly, 
hemihypertrophy, increased 
risk of breast and thyroid 
cancer
STK11 STK11 AMPK-dependent regulator of 
TSC2
Peutz-Jeghers syndrome Hamartomas in GI tract, 
lentigines, increased risk of 
GI and non-GI carcinomas
FLCN Folliculin (FLCN) AMPK-dependent regulator of 
TSC2
BHD syndrome Hamartomas in multiple 
organs (including hair 
follicles), lung cysts 
(spontaneous 
pneumothorax), increased 
risk of renal carcinomas
PKD1 Polycystin 1 (PC1) Regulator of TSC2? Autosomal dominant polycystic 
kidney disease
Renal and extrarenal cysts, 
cardiac valvular and vascular 
defects (including 
intracranial arterial 
aneurysms), hernias, colonic 
diverticulosis
NF1 Neurofibromin 1 (NF1) RAS GAP Neurofibromatosis Neurocutaneous 
hamartomas, endocrine 
tumors, increased risk of 
malignant peripheral nerve 
tumors, sarcomas, myeloid 
leukemia
GI, gastrointestinal; PTEN, phosphatase and tensin homolog (PTEN-hamartoma tumor syndromes include Cowden disease, Bannayan-Riley-
Ruvalcaba syndrome, Proteus syndrome, and Lhermitte-Duclos syndrome); STK11, serine/threonine kinase 11 (also known as LKB1).
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Table 3
Nonrenal side effects of mTOR inhibitors (160,165,201)
Side Effect Frequency
Hypertriglyceridemia High
Hypercholesterolemia High
Mucositis (mouth ulcers, diarrhea) High
Folliculitis, acne, dermatitis High
Anemia, leukopenia, thrombocytopenia Moderate
Impaired wound healing Moderate
Arthralgias Moderate
Insulin resistance Moderate
Liver enzyme elevations Low
Decreased testosterone and spermatogenesis Low
Eyelid or leg edema Low
Angioedema Rare
Lymphedema Rare
Interstitial pneumonitis Rare
Thrombotic microangiopathy Rare
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